Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Juli 2026 09:00 ET | Quelle: OKYO Pharma LTD

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
17. Juli 2026 10:42 ET | Quelle: Compass Therapeutics

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

BOSTON, July 17, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
18. Juni 2026 09:15 ET | Quelle: BiomX

BiomX Provides Update on Defense Technology Portfolio and Growth Strategy

NETANYA, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE), a company that develops and acquires technologies for defense, security, and first-response markets, today...
07. Juni 2026 13:30 ET | Quelle: Antag Therapeutics

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

AT7687 demonstrated a favorable safety and tolerability profile with no adverse GI tolerability signals identifiedOnce-weekly dosing potential and demonstrated target engagement across the doses...
28. Mai 2026 07:00 ET | Quelle: Tiziana Life Sciences Ltd.

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
12. Mai 2026 09:00 ET | Quelle: Resolution Therapeutics

Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026

Resolution Therapeutics will present key preclinical data today on its RMT RTX001 in an oral presentation at the ASGCT Annual Meeting
29. April 2026 07:00 ET | Quelle: OKYO Pharma LTD

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

Robert J. Dempsey, MBA, Chief Executive Officer, to present at EyeceleratorRaj Patil, PhD, Chief Scientific Officer, to present at ARVO LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO...
27. April 2026 09:15 ET | Quelle: Algorhythm Holdings, Inc.

Algorhythm Holdings to Present at the Market Movers Investor Summit

Fort Lauderdale, FL , April 27, 2026 (GLOBE NEWSWIRE) -- Algorhythm Holdings, Inc. (“Algorhythm”) (NASDAQ: RIME), a leading provider of AI-powered logistics solutions, announced today that it will...
23. April 2026 07:00 ET | Quelle: Antag Therapeutics

Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions

Copenhagen, Denmark, 23 April 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today announces that it will...
14. April 2026 07:00 ET | Quelle: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human,...

Nächste Seite